Scientists identify virus-cell interaction that may explain COVID-19's high infection rate

Lehigh researchers quantify the specific interaction between the spike protein of SARS-CoV-2 -- the virus that causes COVID-19 -- with the ACE2 receptors in human cells that may partially explain its high infection rate compared to SARS-CoV-1
29-Mar-2021 11:05 AM EDT, by Lehigh University

Newswise — Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19. This new information could aid in the development of new strategies to block SARS-CoV-2 entry into human cells.

X. Frank Zhang and Wonpil Im knew from recent studies that the interaction between the SARS-CoV-2 spike protein and angiotensin-converting enzyme 2 (ACE2) receptors in human cells is stronger than the interaction between the structurally identical spike protein of SARS-CoV-1, the virus that caused the 2002-2004 SARS outbreak, and the same receptors.

"Our goal was to characterize SARS-CoV-2 and study the protein-protein interactions during its invasion of human cells to provide more insights into the mechanisms that make this first step in its successful invasion process possible," says Zhang, an associate professor in Bioengineering and Mechanical Engineering & Mechanics at Lehigh.

Their findings appear in an article called "Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction" in a special issue of Biophysical Journal"Biophysicists Address Covid-19 Challenges I," published in mid-March. Additional authors include, from Lehigh University: Wenpeng Cao, Decheng Hou and Seonghan Kim in bioengineering; Chuqiao Dong in mechanical engineering and mechanics; and, from Lindsley F. Kimball Research Institute, New York Blood Center, Wanbo Tai and Lanying Du.

Using combined single-molecule force spectroscopy and molecular dynamics simulations, Zhang's and Im's teams were able to identify a previously unknown interaction between ACE2 glycans (sugar groups attached to the surface of proteins) and the SARS-CoV-2 spike. It is this interaction that appears to be responsible for the strengthening of the virus-cell interaction. This may partially explain the higher infection rate of COVID-19 compared to the similar virus that caused the 2002-2004 SARS outbreak, they say.

"We were surprised to find that the specific interaction between ACE2 glycans and the SARS-CoV-2 spike protein is what makes the separation of the virus from cells so difficult," says Im, who is a professor of bioengineering, computer science, chemistry and biological sciences, as well as the Presidential Endowed Chair in Health, Science and Engineering at Lehigh.

To arrive at these findings, the team employed Zhang's innovative single-molecule detection technique, measuring the detachment force of the spike protein-ACE2 receptor interaction. Using the all-atom molecular dynamics simulations of the complex system available in CHARMM-GUI developed by Im, they then identified the detailed structural information in this interaction.

"After we carefully removed all of the ACE2 glycans and measured the force of the interaction, we saw that the strength of the SARS-CoV-2 spike-ACE2 interaction fell back to levels similar to SARS-CoV-1," says Zhang.

"It is possible that this newly-discovered interaction with ACE2 glycans could be a contributing factor to the higher rates of COVID-19 than the structurally similar SARS-CoV-1, which has a weaker interaction," says Zhang. "Our hope is that researchers may be able to use this information to develop new strategies to identify, prevent, treat and vaccinate against COVID-19."

###

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
1.19362